Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Public ClinicalTrials.gov record NCT05797831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Study identification
- NCT ID
- NCT05797831
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 268 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 16, 2023
- Primary completion
- Jul 31, 2025
- Completion
- Jun 30, 2027
- Last update posted
- May 1, 2024
2023 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente Center | Vallejo | California | 94589 | Recruiting |
| Northside Hospital | Atlanta | Georgia | 30342 | Recruiting |
| St. Joseph | Savannah | Georgia | 31405 | Recruiting |
| Dr. Sudarshan K. Sharma, Ltd. | Hinsdale | Illinois | 60521 | Recruiting |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | Recruiting |
| Indiana University | Indianapolis | Indiana | 46202 | Recruiting |
| Maryland Oncology Hematology, P.A. | Silver Spring | Maryland | 20904 | Recruiting |
| Minnesota Oncology Hematology, P.A. | Minneapolis | Minnesota | 55404 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63108 | Recruiting |
| Women's Cancer Center of Nevada | Las Vegas | Nevada | 89106 | Recruiting |
| Good Samaritan Hospital Medical Center | West Islip | New York | 11795 | Recruiting |
| FirstHealth Carolinas | Pinehurst | North Carolina | 28374 | Recruiting |
| OhioHealth Institute | Columbus | Ohio | 43214 | Recruiting |
| Oklahoma Cancer Specialists and Research Institute | Tulsa | Oklahoma | 74146 | Recruiting |
| Oncology Associates of Oregon | Eugene | Oregon | 97401 | Recruiting |
| Northwest Cancer Specialists | Portland | Oregon | 97227 | Recruiting |
| Texas Oncology-Austin Central | Austin | Texas | 78745 | Recruiting |
| Texas Oncology-Fort Worth Cancer Center | Fort Worth | Texas | 76104 | Recruiting |
| Texas Oncology-San Antonio Medical Center | San Antonio | Texas | 78130 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05797831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 1, 2024 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05797831 live on ClinicalTrials.gov.